

**WIN SYMPOSIUM 29-30 October 2022 Barcelona, Spain**  
**INTEGRATING GENOMICS AND TRANSCRIPTOMICS TO RESHAPE PRECISION ONCOLOGY:**  
**A WINNING STRATEGY**

**Saturday October 29**

**WELCOME AND OPENING REMARKS**

<b>Welcome and opening remarks</b>	Richard L. Schilsky	Chairman WIN Consortium, Villejuif, France
	Josep Taberero	Vice-Chairman WIN Consortium, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
<b>Opening Keynote Lecture</b> Re-imagining the (r)evolution in the Precision Oncology paradigm: the future is now	Vivek Subbiah	The University of Texas, MD Anderson Cancer Center, Houston, USA

**SESSION 1 - BEYOND DNA TESTING: THE PLACE OF TRANSCRIPTOMICS IN PRECISION ONCOLOGY**

<b>Keynote Lecture</b> Expression profiling to discover molecularly and clinically distinct cancer subtypes and to predict response to therapy	Louis M. Staudt	National Cancer Institute (NCI), Bethesda, USA
<b>Keynote Lecture</b> Functional genomics to identify cancer vulnerabilities	René Bernards	Netherlands Cancer Institute (NKI), Amsterdam, The Netherlands
Accelerating precision oncology using multi-omics and AI	Olivier Elemento	Weill Cornell Medicine, New York, USA
<i>Coffee break, networking</i>		
Modeling gene regulatory processes to understand cancer and identify therapies	John Quackenbush	Harvard T.H. Chan School of Public Health, Boston, USA
SIMS and Digital Display Precision Predictor algorithms	Vladimir Lazar	WIN Consortium, Villejuif, France
Harnessing a synthetic lethality analysis for patient stratification: key role of transcriptomics	Eytan Ruppin	National Institute of Health (NIH), Bethesda, USA

Panel Discussion

*Lunch, poster viewing and networking*

**SESSION 2 – INNOVATION IN CLINICAL TRIALS TO ENABLE FUTURE EFFICIENT TREATMENTS**

<b>Keynote opening Lecture</b> Bringing single cell analyses to the clinics	Andrea Califano	Columbia University Medical Center, New York, USA
<b>Keynote lecture</b> Identifying new uses for approved, targeted drugs: Updates from the ASCO TAPUR study	Richard L. Schilsky	WIN Consortium, Villejuif, France
Genomic and transcriptomic signatures and innovation in CRC cancers	Josep Taberero	Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
Phase 3 trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma: comprehensive tumor genomic and transcriptomic analyses	Jean-François Martini	Pfizer, Inc., San Diego, USA
IO in combination: the SPRING trial tri-therapy approach	Benjamin Solomon	Avera Cancer Institute, Sioux Falls, USA

*Coffee break, networking*

Satellite Symposium

*Welcome reception*

*Symposium Dinner*

**WIN SYMPOSIUM 29-30 October 2022 Barcelona, Spain**  
**INTEGRATING GENOMICS AND TRANSCRIPTOMICS TO RESHAPE PRECISION ONCOLOGY:**  
**A WINNING STRATEGY**

**Sunday October 30**

**SESSION 3 – DISRUPTIVE CONCEPTS AND METHODOLOGICAL INNOVATIONS IN NSCLC: MEET THE EXPERTS**

<b>Keynote lecture</b> Advances in Lung Cancer	Solange Peters	President ESMO, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
Early stage lung cancer: challenge and opportunity	Haiquan Chen	Fudan University, Shanghai, China
Neoadjuvant and adjuvant strategies in NSCLC	Enriqueta Felip	Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
A focus on emerging paradigms in the treatment of early NSCLC	Jair Bar	Chaim Sheba Medical Center, Ramat Gan, Israel
From chest x ray to AI-assisted lung cancer screening and early detection program in Israel	Amir Onn	Chaim Sheba Medical Center, Ramat Gan, Israel
New drugs for SCLC	Pilar Garrido	Universidad de Alcalá, Madrid, Spain

*Coffee Break, networking*

**SESSION 4 - WIN FIRST INTERNATIONAL MOLECULAR TUMOR BOARD: A STRATEGIC PLACE IN ADVANCING PRECISION ONCOLOGY**

<b>First WIN International Molecular Tumor Board</b> Introduction Patients' cases presentation by investigators. Discussion and treatment recommendation.	Moderator Razelle Kurzrock	WIN Consortium, Villejuif, France
Panel Discussion and Q&A from the audience		

*Lunch, poster viewing and networking*

**SESSION 5 – WHAT IS NEW IN BREAST, CRC, OVARY, HEAD & NECK, PEDIATRIC AND OTHER CANCERS?**

<b>Opening Keynote Lecture</b> The BIG AURORA molecular screening program for metastatic breast cancer: first results	Martine Piccart	Institut Jules Bordet, Brussels, Belgium
<b>Keynote Lecture</b> Novel CRC insights based on combined genomic and transcriptomic data at both bulk and single cell level, leading to new therapeutically relevant CRC classification	Sabine Tejpar	University of Leuven, Belgium
Serial profiling in metastatic CRC; beyond the tip of the iceberg	Gerald Batist	Segal Cancer Centre, Lady Davis Institute at the JGH, McGill University, Montréal, Canada
Paradigm shift in treatment of ovarian cancers	Matthew Ellis	AstraZeneca, Gaithersburg, USA
Novel strategies in head & neck cancers	Christophe Le Tourneau	Institut Curie, Paris, France
Novel strategies in prostate cancer (TBC) or Novel strategies in melanoma (TBC)		
Pediatric European Precision Cancer Medicine Program - Facing cancer complexity	Birgit Geoerger	Gustave Roussy, Villejuif, France ITCC

**BEST TWO POSTERS' PRESENTATIONS AND AWARDS**

Josep Tabernero, Vice-Chairman WIN Consortium, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain  
 Amir Onn, Head of the Standard Operating Procedures and Repository Committee, WIN Consortium;  
 Chair, Institute of Pulmonary Medicine, Sheba Medical Center, Israel

**CONCLUSIONS**

Richard L. Schilsky, Chairman WIN Consortium